METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New IV drug tested for advanced fatty liver disease
Disease control CompletedThis study tested the safety and early effects of an experimental medicine called BI 770371 for people with liver scarring (cirrhosis) caused by MASH, a serious form of fatty liver disease. About 28 participants were randomly assigned to receive either the drug or a placebo (dumm…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Doctors and patients surveyed on understanding of silent liver disease
Knowledge-focused CompletedThis study was a survey to understand how much doctors, patients, and at-risk people know about a liver condition called MASH and its links to heart and kidney problems. Over 1,300 participants from five countries completed a 25-minute online questionnaire. The study did not test…
Matched conditions: METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH)
Sponsor: Novo Nordisk A/S • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:40 UTC